Nefrosana - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 88,315 | 213,159 | 314,097 | 407,413 | 488,404 | 723,323 | 847,932 | 887,092 |
| Profit before tax | -141,632 | -25,854 | 30,627 | 59,883 | -21,429 | 19,215 | 82,204 | 102,800 |
| Net profit | -141,632 | -25,854 | 30,627 | 59,883 | -21,429 | 19,215 | 82,204 | 97,348 |
| Equity | -156,596 | -182,450 | -151,823 | -91,940 | -113,369 | -94,154 | -11,950 | 85,462 |
| Liabilities | 307,678 | 313,336 | 296,603 | 270,709 | 372,107 | 318,067 | 268,410 | 205,336 |
| Non-current assets | 126,936 | 90,798 | 56,420 | 40,239 | 109,587 | 41,476 | 28,969 | 29,345 |
| Current assets | 24,023 | 39,907 | 89,563 | 138,274 | 148,652 | 181,926 | 227,562 | 261,184 |
| Total assets | 150,959 | 130,705 | 145,983 | 178,513 | 258,239 | 223,402 | 256,531 | 290,529 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 69,306 | 80,680 | 89,171 |
| Social insurance contributions | - | - | - | - | - | 82,907 | 96,660 | 105,696 |
|
Financial indicators
|
||||||||
| Revenue change y/y | - | +141.4% | +47.4% | +29.7% | +19.9% | +48.1% | +17.2% | +4.6% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | -93.8% | -19.8% | 21.0% | 33.5% | -8.3% | 8.6% | 32.0% | 33.5% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | - | - | - | - | - | - | - | 113.9% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | -160.4% | -12.1% | 9.8% | 14.7% | -4.4% | 2.7% | 9.7% | 11.0% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | -160.4% | -12.1% | 9.8% | 14.7% | -4.4% | 2.7% | 9.7% | 11.6% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | - | - | - | - | - | - | - | 2.4 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 11,519 | 17,053 | 24,161 | 23,505 | 22,033 | 30,349 | 30,374 | 30,855 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Nefrosana - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2024-11-18 | 2024-11-24 | 0.02 |
| 2021-12-16 | 2021-12-19 | 0.03 |
Nefrosana - VMI tax arrears
The company had no tax arrears (debts) to the State Tax Inspectorate
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Nefrosana, UAB (code 304347275) is a Private Limited Liability Company engaged in medical specialists activities. In 2025, the company generated revenue of €887.1K and net profit of €97.3K, with a profit margin of 11.0%. Revenue increased by 4.6% year on year and by 22.6% over two years, showing a steady expansion trend. Profitability also improved over the period, rising from €19.2K in 2023 to €82.2K in 2024 and €97.3K in 2025. The latest balance sheet shows total assets of €290.5K, equity of €85.5K and liabilities of €205.3K. Long-term assets were €29.3K, while short-term assets reached €261.2K, indicating a liquid asset structure. Key ratios point to solid operating efficiency, with asset turnover at 3.05x and debt-to-equity at 2.40. Return on equity and return on assets were strong in 2025. Based on staffing data, revenue per employee was €31.7K and profit per employee was €3.5K.